Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis

•Reducing treatment burden is a high priority for people living with CF.•Standard of care involves the use of multiple nebulized therapies which are time consuming.•Prescription refills for nebulized dornase alfa and hypertonic saline decreased in the first year post-ETI.•Several ongoing studies are...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cystic fibrosis 2022-11, Vol.21 (6), p.1080-1081
Main Authors: Song, Jia Tong, Desai, Sameer, Franciosi, Alessandro N., Dagenais, Renee V.E., Quon, Bradley S.
Format: Article
Language:English
Subjects:
Aminophenols
Benzodioxoles
Chloride Channel Agonists
Cystic fibrosis
Cystic Fibrosis - drug therapy
Cystic Fibrosis - genetics
Cystic Fibrosis Transmembrane Conductance Regulator - genetics
Drug Combinations
Elexacaftor
Humans
Medication adherence
Pyrazoles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Reducing treatment burden is a high priority for people living with CF.•Standard of care involves the use of multiple nebulized therapies which are time consuming.•Prescription refills for nebulized dornase alfa and hypertonic saline decreased in the first year post-ETI.•Several ongoing studies are evaluating the safety of withdrawing nebulized therapies post-ETI.
ISSN:1569-1993
1873-5010
DOI:10.1016/j.jcf.2022.05.005